Webcasts

Webcast: Current Risk Assessment and Treatment of Patients With PBC

03/16/2026

This webcast reviews the evolving approach to risk stratification and treatment in primary biliary cholangitis (PBC), highlighting how prognostic models, liver stiffness measurement, and biochemical response can help predict long-term outcomes. The presentation explains the role of ursodeoxycholic acid (UDCA) as first-line therapy, the importance of monitoring alkaline phosphatase and bilirubin, and how tools like the GLOBE score and FibroScan are improving personalized care for patients with PBC. It also covers newly approved second-line therapies, including elafibranor and seladelpar, with a focus on biochemical remission, itch reduction, and quality of life. This session is a practical update for clinicians managing PBC, cholestatic liver disease, fibrosis risk, and long-term treatment strategy.